New venture capital fund focuses on improving care for heart disease and stroke Rates of cardiovascular disease are rising and costs are approaching $1 trillion annually in the United States. To ensure that effective innovations are rapidly introduced into the healthcare system, Philips, the American Heart Association and UPMC have partnered to create the $30 million Cardeation Capital venture capital fund. The new fund will invest in emerging healthcare companies that can measurably affect the prevention and treatment of cardiovascular diseases and stroke — and their risk factors, such as diabetes. Cardeation Capital’s investors will fund best-in-class technology companies with scalable products and services that address healthcare delivery and health management.
You are about to visit a Philips global content page
ContinueThe information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).
By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.